Abbott Labs Jumps After Q2 Beat, Raises 2026 Profit View
Abbott Laboratories (ABT) shares jumped in early trading Thursday after the company reported better-than-expected second-quarter results and raised its 2026 profit guidance.
Key Numbers
Shares of Abbott Laboratories (NYSE: ABT) rose sharply on Thursday after the healthcare company posted second-quarter 2026 results that exceeded analyst expectations and lifted its full-year profit forecast.
Key Financial Results
| Metric | Q2 2026 | vs. Estimates |
|---|---|---|
| Revenue | Not disclosed | Beat |
| Earnings per share (EPS) | Not disclosed | Beat |
| 2026 profit guidance | Raised | - |
Note: Specific figures were not provided in the initial release, but the company confirmed it surpassed consensus estimates.
Highlights from the Statement
Management attributed the strong quarterly performance to robust sales in medical devices and diagnostics, which underpinned the decision to raise the 2026 earnings outlook.
Future Guidance
Abbott raised its 2026 profit view, though the new range was not immediately disclosed. Full details are expected in the upcoming conference call.
Impact on the Stock
ABT stock surged in early trading, reflecting investor optimism over the earnings beat and improved guidance.
What This Means for Investors
Abbott's strong results and raised guidance signal solid demand for its healthcare products. Investors should await the full earnings release to assess the sustainability of this growth.
Frequently Asked Questions
Found this useful? Share it